Egfr-Mutated Lung Cancer, Study Phase 3 Adaura: "79% of Patients Alive at 8 Years with Osimertinib"
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.7 Articles
7 Articles
Il Tempo
Rome, 16 Sep. (Adnkronos Salute) - Lung cancer is the main cause of death for cancer globally, representing almost one in five (19%) deaths for cancer. Lung cancer is generally divided into non-small cell (Nsclc) and small cell lung cancer; 80-85% of patients receive a diagnosis of Nsclc. About 75% of patients with Nsclcc receive an advanced disease diagnosis, while about 25-30% have a resectable disease at the time of diagnosis. About 10-15% of…
Lung cancer is the main cause of death for cancer globally, representing almost one in five (19%) deaths for cancer. Lung cancer is generally divided into non-small cell (Nsclc) and small cell (Nsclc) lung cancer; 80-85% of patients receive a diagnosis of Nsclc. About [...]
notizie.it
Rec News | Lontani dal mainstream(Adnkronos) - Lung cancer is the main cause of death for cancer globally, representing almost one in five (19%) deaths for cancer.
The eight-year results of the Phase III ADAURA study confirm a significant benefit on overall survival with osimertinib in patients with EGFR mutation NSCLC after complete tumour resection The post lung cancer with EGFR mutation. ADAURA study: 79% of patients are alive with osimertinib after eight years appeared first on Quotidiano Sanità.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
